Last reviewed · How we verify
Triamcinolone + Bevacizumab
Triamcinolone reduces inflammation via glucocorticoid receptor activation, while bevacizumab inhibits vascular endothelial growth factor (VEGF) to suppress neovascularization and reduce vascular permeability.
Triamcinolone reduces inflammation via glucocorticoid receptor activation, while bevacizumab inhibits vascular endothelial growth factor (VEGF) to suppress neovascularization and reduce vascular permeability. Used for Diabetic macular edema, Retinal vein occlusion with macular edema, Age-related macular degeneration.
At a glance
| Generic name | Triamcinolone + Bevacizumab |
|---|---|
| Also known as | triamcinolone + avastin |
| Sponsor | Rubens Belfort Jr. |
| Drug class | Corticosteroid + Monoclonal antibody (anti-VEGF) |
| Target | Glucocorticoid receptor; VEGF (vascular endothelial growth factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This combination targets both inflammatory and angiogenic pathways in ocular disease. Triamcinolone is a corticosteroid that suppresses immune-mediated inflammation, while bevacizumab is a monoclonal antibody against VEGF that reduces pathological blood vessel formation and vascular leakage. Together, they address multiple pathogenic mechanisms in retinal and choroidal diseases.
Approved indications
- Diabetic macular edema
- Retinal vein occlusion with macular edema
- Age-related macular degeneration
- Choroidal neovascularization
Common side effects
- Elevated intraocular pressure
- Cataract progression
- Endophthalmitis
- Retinal detachment
- Systemic hypertension
- Thromboembolic events
Key clinical trials
- Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids. (PHASE4)
- Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients (PHASE4)
- IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes (NA)
- Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization (PHASE2, PHASE3)
- Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study (PHASE3)
- Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO (PHASE4)
- Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion (NA)
- Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triamcinolone + Bevacizumab CI brief — competitive landscape report
- Triamcinolone + Bevacizumab updates RSS · CI watch RSS
- Rubens Belfort Jr. portfolio CI